Rgene Corporation

Rgene Corporation is a biotechnology company. Rgene is co-developing three drug products with ABVC Biopharma, Inc.: 1. RGC-1501, for the treatment of non-small cell lung cancer (NSCLC); 2. RGC-1502, for the treatment of non-small cell lung cancer (NSCLC), which has completed Phase II clinical studies in accordance with U.S. FDA IND regulatory requirements; 3. RGC-1503, for the treatment of pancreatic cancer and colorectal cancer.